Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes.
(2022) Diabetes Research and Clinical Practice — Vol. 190, p. 109980 [1-8] (2022)
Files
2022_Neves_Diabetes_Res_Clin_Pract.pdf
Open Access - Adobe PDF
- 2.41 MB
Details
- Authors
- Abstract
- Prediabetes affects at least 1 in 3 adults in the U.S. and 1 in 5 in Europe. Although guidelines advocate aggressive management of lipid parameters in diabetes, most guidelines do not address treatment of dyslipidemia in prediabetes despite the increased atherosclerotic cardiovascular disease (ASCVD) risk. Several criteria are used to diagnose prediabetes: impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and HbA1c of 5.7-6.4%. Individuals with prediabetes have a greater risk of diabetes, a higher prevalence of dyslipidemia with a more atherogenic lipid profile and an increased risk of ASCVD. In addition to calculating ASCVD risk using traditional methods, an OGTT may further stratify risk. Those with 1-hour plasma glucose ≥8.6 mmol/L (155 mg/dL) and/or 2-hour ≥7.8 mmol/L (140 mg/dL) (IGT) have a greater risk of ASCVD. Diet and lifestyle modification are fundamental in prediabetes. Statins, ezetimibe and PCSK9 inhibitors are recommended in people requiring pharmacotherapy. Although high-intensity statins may increase risk of diabetes, this is acceptable because of the greater reduction of ASCVD. The LDL-C goal in prediabetes should be individualized. In those with IGT and/or elevated 1-hour plasma glucose, the same intensive approach to dyslipidemia as recommended for diabetes should be considered, particularly if other ASCVD risk factors are present.
- Affiliations
Citations
Neves, J. S., Newman, C., Bostrom, J. A., Buysschaert, M., Newman, J. D., Medina, J. L., Goldberg, I. J., & Bergman, M. (2022). Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. Diabetes Research and Clinical Practice, 190, 109980 [1-8]. https://doi.org/10.1016/j.diabres.2022.109980 (Original work published 2022)